XVIVO is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. Our mission is to increase the survival rates of patients awaiting transplantation by providing more effective, clinically proven innovative products that both increase the availability of acceptable donors organs and improve survival after transplantation. We are committed to provide our customers with solutions and systems that can improve the transplant process outcome, facilitate the work for the transplant team, and enhance the long term outcomes and quality of life of the transplant recipient.
Quote | Xvivo Perfusion Ab Ord (OTCMKTS:XVIPF)
Last: | $32.20 |
---|---|
Change Percent: | 0.0% |
Open: | $32.2 |
Close: | $32.20 |
High: | $32.2 |
Low: | $32.2 |
Volume: | 130 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Xvivo Perfusion Ab Ord (OTCMKTS:XVIPF)
GOTHENBURG, SWEDEN / ACCESSWIRE / April 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) First quarter 2024 (Jan 1 - Mar 31) • Net sales amounted to SEK 186.0 million (140.6), corresponding to an increase of 32 percent in SEK and equivalent increase, 32 percent, adjusted ...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 11, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, at the 2024 International Society of Heart and Lung Transplantation meeting in Prague, Czech Republic, the results from XVIVO's clinical trial, NIHP2019, in heart transplantation were pres...
Message Board Posts | Xvivo Perfusion Ab Ord (OTCMKTS:XVIPF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Xvivo Perfusion Ab Ord Company Name:
XVIPF Stock Symbol:
OTCMKTS Market:
GOTHENBURG, SWEDEN / ACCESSWIRE / April 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) First quarter 2024 (Jan 1 - Mar 31) • Net sales amounted to SEK 186.0 million (140.6), corresponding to an increase of 32 percent in SEK and equivalent increase, 32 percent, adjusted ...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 11, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, at the 2024 International Society of Heart and Lung Transplantation meeting in Prague, Czech Republic, the results from XVIVO's clinical trial, NIHP2019, in heart transplantation were pres...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 4, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today XVIVO Perfusion AB (publ) publish the Annual Report for 2023. The Annual Report is attached to this press release in pdf format and in ESEF format (European Single Electronic Format) and is...